• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»CRISPR gene editing

Scribe Therapeutics deepens in vivo CRISPR validation with second Eli Lilly collaboration milestone

By Pallavi Madhiraju on February 18, 2026   Pharma & Biotech  

Scribe Therapeutics deepens in vivo CRISPR validation with second Eli Lilly collaboration milestone

Scribe Therapeutics hits a second in vivo CRISPR milestone with Eli Lilly. Explore what this changes for gene editing platforms and future therapies.

Can CRISPR editing of NRF2 reverse resistance in head and neck squamous cell carcinoma?

By Pallavi Madhiraju on January 24, 2026   Pharma & Biotech  

Can CRISPR editing of NRF2 reverse resistance in head and neck squamous cell carcinoma?

CorriXR’s new data show CRISPR-based NRF2 disruption restores chemo response in squamous tumors. Find out what this could mean for HNSCC treatment.

Recent Posts

  • Medtronic’s SPR Therapeutics deal signals a sharper move into earlier chronic pain intervention
  • Why Donor Alliance and LifeSource are building a new model for transplant system performance
  • Papillary NMIBC could become the next commercial test for ImmunityBio’s ANKTIVA franchise
  • Is Avvio Medical building the next outpatient frontier in kidney stone and ureteral stone therapy?
  • Phoenix and Raven launch direct-to-patient generic semaglutide after Health Canada approval
  • How Codexis, Inc.’s ECO Synthesis platform could reshape industrial RNA production workflows
  • How the PharmAla Biotech Holdings Inc. and Jupiter Neurosciences, Inc. deal reflects changing investor expectations in psychedelics
  • Could Hyundai Bioscience’s XAFTY become a crisis-response antiviral for Ebola and hantavirus?
  • How Araceli Biosciences is pushing live-cell imaging into ultra-high-throughput drug screening
  • Regeneron’s $2.2bn Parabilis pact signals rising interest in next-generation conjugates
  • Samsung Bioepis targets Japan’s autoimmune market with ustekinumab biosimilar debut
  • Bayer’s asundexian FDA priority review puts Factor XIa inhibition closer to a real stroke prevention test
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes